Demand for anti-covid drugs increased by 51%

Against the backdrop of a sharp increase in the incidence of CORONAVIRUS in RUSSIA, citizens have become much more interested in drugs that are mentioned in the 13th version of the recommendations of the Ministry of HEALTH for the prevention, diagnosis and treatment of symptoms of covid-19 . According to the Chestny Znak labeling system, in the first three weeks of October, demand for a range of medicines increased by 51% compared to the same period in September.

Demand increased the most for sarilumab (by 198%) and remdesivir (by 157%), which the Ministry of Health recommends for use in pathological changes in the lungs. At the same time, the recommendations of the ministry indicate that this can be done under certain conditions and in certain dosages, depending on the patient's condition.

Demand for antibiotics, antiviral and antipyretic drugs also increased: umifenovir (+70%), paracetamol (+34%), interferon alfa-2b (+61%), apixaban (+58%), dexamethasone (+47%). At the same time, the Ministry of Health indicated that in the case of, for example, umifenovir, there is no evidence of efficacy and safety in case of use by patients with COVID-19.

In addition, demand for anticoagulants increased — sodium enoxaparin (+43%), sodium dalteparin (+39%), sodium heparin (+37%).